AMRN: 阿玛琳

AMRN新闻

• 15:56 FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
• 14:04 Here's Why You Should Add EYPT Stock to Your Portfolio Now
• 13:33 RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
• 16:38 LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
• 12:59 Here's Why You Should Add ANRO Stock to Your Portfolio Now
• 12:52 Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
• 16:40 BMY Reports Mixed Phase III Trial Results, Stock Down
• 15:24 Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
• 14:55 PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
• 16:55 argenx Meets Primary Endpoint in Phase II Celiac Disease Study
• 14:53 EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
• 13:37 Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
• 13:57 Here's Why You Should Add LPCN Stock to Your Portfolio Now
• 15:08 ETON Stock Surges 108% in Six Months: Here's What You Need to Know
• 12:55 Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
• 11:50 Teva's Branded Drugs Take Center Stage in Its Growth Strategy
• 14:48 RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
• 14:56 RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
• 15:30 Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
• 19:54 Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
• 14:46 TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
• 13:40 Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
• 16:33 BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
• 22:13 Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript